



KANSAI (Saito & Kobe)

Striving to be the World's No. 1 Bio-cluster

Cluster Vision

Located in northern Osaka (Saito) and focusing on drug discovery, the Senri Life Science Foundation (SenriLF) and the Foundation for Biomedical Research and Innovation (FBRI), which is located in Kobe and focuses on advanced medical practice, are collectively known as "Japan's No. 1 bio-cluster" and aim to be an internationally competitive bio-cluster with world-class infrastructure for life science research and Japan's largest concentration of bio-industry. We will strive to be "the world's No. 1 bio-cluster". In drug discovery, researchers' seeds are linked to commercialization efforts such as technology transfers and set up of venture corporations. We also convey industry needs to research institutes and enhance the "Biomedical Chain" (system to transfer technology and start a new research upon needs). We will construct a "Medical Innovation System" (to make medical/health services efficient and practical by combining researchers' and corporations' technologies) from citizenry's perspective on advanced/preventive medical services. We promote corporations' novel drug development, safe and reliable provision of medical care, and scientific support to promote health by sharing infrastructure in both regions.

Project Overview

1. Fundamental Research

- (1) Vaccine Immunity and Infectious Diseases
We pursue infrastructure development to realize clinical vaccine development to prevent malaria, influenza, and other illnesses.
- (2) Advanced Drug Discovery for Cancer
We pursue development of various novel molecular-targeted drugs by studying characteristics of cancer and cancer stem cells.
- (3) Establishment of Regenerative Medicine
We aim to realize cell therapy using human ES cells for Parkinson's disease to provide safe and advanced medical care and establish safe technology for use of human ES cells.
- (4) Research on Lifestyle-related Diseases Treatment/Prevention
We work on technological development to ascertain citizens' living conditions and urge them to provide information voluntarily. We support construction of a next generation cohort research infrastructure using IT. These are to link health mind to science.

2. Mechanism for Commercialization/Realization of Research Results

- "Biomedical Chain"
- support for commercialization/realization of research results
 - interfacing with corporations by drug discovery patent marketing and the Bio Matching System
 - fund networking through venture capital
- "Medical Innovation System"
- fundamental development of advanced medical innovation by participation of citizens
 - development of high-quality safe information providing systems for advanced medical care
 - We provide business consultation/training on intellectual property, develop systems to utilize intellectual property, and provide personnel training needed at biomedical venture corporations in Kansai.

Project Director
Michihiro Tsuchiya



Mitsubishi Tanabe Pharma Corporation
Director

Striving to be the World's No.1 Bio-cluster

Biomedical Cluster Kansai will work to form new biomedical clusters maximizing the research infrastructure for both drug discovery (Saito) and regenerative medicine (Kobe) under the Biomedical Cluster Kansai Project. Industry-academic-government collaboration is an important strategy for corporations. Searching for novel drug discovery targets and drug discovery-related technologies is extremely important for drug discovery research but companies cannot do all of this work themselves. The search for drug discovery targets and technology will not lead to results right away, but producing innovative medical drugs is essential. Therefore, we expect results from Universities and public organizations with regard to this fundamental research. Our cluster business includes community improvement and we will train human resources continuously and proactively for future progress.

As Chief Director, I will do my best to make Kansai an international biomedical cluster.

Cluster Headquarters

- President.....Hiroo Imura (Chairman, Foundation for Biomedical Research and Innovation)
 Adviser.....Tadamitsu Kishimoto (Chairman, Senri Life Science Foundation)
 Project Director.....Michihiro Tsuchiya (Director, Mitsubishi Tanabe Pharma)
 (Northern Osaka Region)
 Chief Scientist.....Koichi Yamanishi (Director General, National Institute of Biomedical Innovation)
 Chief Science and Technology Coordinator...Tutomu Takagi
 Science and Technology Coordinator...Hideki Yanagi
 Commercial Promotion Fellow...Hiromichi Imoto, Fumiko Shimoda
 (Kobe Region)
 Chief Scientist.....Shin-Ichi Nishikawa
 (Deputy Director, Center for Developmental Biology)
 Science and Technology Coordinator...Ryoji Yano, Hideki Takeda, Yoshikuni Ito, Yoshiaki Fujihara

Core Organizations


Senri Life Science Foundation, Foundation for Biomedical Research and Innovation

Participating Research Organizations (Bold: Core Research Organizations)

Industry...KAN Research Institute, Inc., Genomix Co., LTD., Technoview, Inc., KOKEN CO., LTD, TakashimaEngineering, Fuji Biomedix Co., Ltd., Sysmex Corporation, Novo Nordisk Pharma, The Research Foundation for Microbial Diseases of Osaka University, Kirin Pharma Company, Limited, Genomidea Inc., Link Genomics, Inc., Asubio Pharma Co., Ltd.
 Academia...**Kyoto University, Osaka University, Kobe University,** Shiga University of Medical Science, University of Cambridge (UK), Institute of Genetics and Molecular and Cellular Biology (IGBMC in France), National University of Singapore, Lund University
 Government...**National Institute of Biomedical Innovation (NIBIO),** **Center for Developmental Biology,** National Cardiovascular Center, Molecular Imaging Research Program, National Hospital Organization Osaka National Hospital, Foundation for Biomedical Research and Innovation, Translational Research Informatics Center, National Hospital Organization Kyoto Medical Center, National Institute of Advanced Industrial Science and Technology (AIST), Joslin Diabetes Center, Medicon Valley Alliance

3. Kansai Program

- (1) Development of an International Value Chain for In Silico Drug Discovery
We will increase the international competitiveness of Japan's drug discovery by supplementing in silico drug discovery technologies through collaboration with influential clusters in Europe (University of Cambridge in the UK and Alsace BioValley in France).
- (2) International Collaboration Program on Diabetes Treatment/Prevention
We analyze diabetes pathogenesis in various races and promote the development of prevention/diagnostic methods focusing on various pathogenic patterns due to race with the collaboration of the Medicon Valley Alliance, Singapore, etc. We aim to play the key role in Asian diabetes research.



Knowledge Cluster Initiative (Stage-II)

